Issue 14, 2016

Sumac as a novel adjunctive treatment in hypertension: a randomized, double-blind, placebo-controlled clinical trial

Abstract

Background: Sumac (Rhus coriaria L., Anacardiaceae) is a medicinal plant traditionally used for the treatment of cardiovascular disorders. This study was designed to evaluate the effects of Sumac fruits in hypertensive patients. Material and Methods: a randomized, double-blind, placebo-controlled clinical trial was conducted on 80 hypertensive patients who were receiving captopril (25 mg day−1). The patients were randomly divided into 2 groups: the first group received R. coriaria fruit capsules (500 mg twice a day) and captopril (25 mg once a day), and the second one received placebo capsules (500 mg starch twice a day) and captopril (25 mg once a day), for 8 weeks. Blood pressure (BP) and body weight index (BMI) in all patients were determined every week. Phytochemical analysis of R. coriaria fruits was performed by using HPLC-DAD/QTOF-MS for analysing its phenolic compounds. Results: data indicated that hypertension was decreased significantly in R. coriaria group compared to baseline and placebo groups after 8 weeks, but BMI did not demonstrate a marked change in comparison with baseline and placebo groups. Moreover, the most abundant phenolic compounds identified in R. coriaria fruits were luteolin, apigenin, and quercetin flavonoids. Discussion: this finding suggests that R. coriaria fruits could be used as an effective natural remedy for management of hypertension. Since flavonoids were the main chemical constituents of this plant, its antihypertensive activity could be attributed to such compounds.

Graphical abstract: Sumac as a novel adjunctive treatment in hypertension: a randomized, double-blind, placebo-controlled clinical trial

Article information

Article type
Paper
Submitted
30 Oct 2015
Accepted
05 Jan 2016
First published
19 Jan 2016

RSC Adv., 2016,6, 11507-11512

Author version available

Sumac as a novel adjunctive treatment in hypertension: a randomized, double-blind, placebo-controlled clinical trial

H. Ardalani, M. H. Moghadam, R. Rahimi, J. Soltani, A. Mozayanimonfared, M. Moradi and A. Azizi, RSC Adv., 2016, 6, 11507 DOI: 10.1039/C5RA22840A

To request permission to reproduce material from this article, please go to the Copyright Clearance Center request page.

If you are an author contributing to an RSC publication, you do not need to request permission provided correct acknowledgement is given.

If you are the author of this article, you do not need to request permission to reproduce figures and diagrams provided correct acknowledgement is given. If you want to reproduce the whole article in a third-party publication (excluding your thesis/dissertation for which permission is not required) please go to the Copyright Clearance Center request page.

Read more about how to correctly acknowledge RSC content.

Social activity

Spotlight

Advertisements